Advances in medication for HIV prevention and AIDS treatment


in Science

Truvada, a brand name for a cocktail of emtricitabine and tenofovir, is a daily oral prophylactic medication which has been found to be highly effective at preventing the uninfected from catching HIV. Now, a new drug is being tested which could provide the same protection in a way that’s more convenient and would be easier for people to use:

Cabotegravir is an integrase inhibitor—meaning that it works by stopping hiv copying its genome into the chromosomes of its host cells, an important stage in its life cycle. Unlike Truvada, which must be taken daily, by mouth, prophylactic cabotegravir is delivered as an injection once every two months.

In combination with the antiretroviral (ARV) drug rilpivirine, cabotegravir may also allow those who are already infected with HIV to be treated with periodic infections rather than multiple daily pills.

{ 2 comments… read them below or add one }

anon July 23, 2020 at 6:15 pm

Could make eradication of the disease possible with universal availability.

alena prazak July 24, 2020 at 12:09 pm

That is a great advance. Do you know how much the treatment costs? Would it be affordable for the people who need it the most and who have the least resources?

Leave a Comment

Previous post:

Next post: